{
    "clinical_study": {
        "@rank": "156433", 
        "arm_group": [
            {
                "arm_group_label": "MDS", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after Complete Response (CR) if treatment has been administered for 24 weeks and 2 doses have been administered after CR."
            }, 
            {
                "arm_group_label": "Relapsed/Refractory MM", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg by IV infusion Q2W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after stringent complete response (sCR) if treatment has been administered for 24 weeks and 2 doses have been administered after sCR."
            }, 
            {
                "arm_group_label": "HL", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after Complete Response (CR) if treatment has been administered for 24 weeks and 2 doses have been administered after CR."
            }, 
            {
                "arm_group_label": "MLBCL/PD-L1 positive NHL", 
                "arm_group_type": "Experimental", 
                "description": "10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after Complete Response (CR) if treatment has been administered for 24 weeks and 2 doses have been administered after CR."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to evaluate the safety, tolerability, and efficacy of\n      pembrolizumab (MK-3475) in hematologic malignancies (myelodysplastic syndrome [MDS],\n      multiple myeloma [MM], Hodgkin's lymphoma [HL], mediastinal large B cell lymphoma [MLBCL],\n      and non-Hodgkin's lymphoma [NHL])."
        }, 
        "brief_title": "A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndrome", 
            "Multiple Myeloma", 
            "Hodgkin's Lymphoma", 
            "Non-Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have primary or secondary myelodysplastic syndrome (MDS) and have failed to respond\n             to at least 4 cycles of hypomethylating agent, OR Have a confirmed diagnosis of\n             relapsed/refractory multiple myeloma (R/R MM) that have failed at least two lines of\n             prior therapy including bortezomib and an IMiD (thalidomide, pomalidomide,\n             lenalidomide), OR Have relapsed/refractory nodular sclerosing or mixed cellularity\n             Hodgkin lymphoma, relapsed/refractory mediastinal large B cell lymphoma, or any other\n             relapsed/ refractory programmed cell death ligand 1 (PD-L1) positive non-Hodgkin\n             lymphoma that have failed, are ineligible for, or refused a stem cell transplant.\n             Hodgkin lymphoma participants must have relapsed after treatment with or failed to\n             respond to brentuximab vedotin.\n\n          -  Have measureable disease\n\n          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)\n             Performance Scale\n\n          -  Demonstrate adequate organ function\n\n          -  For MDS: Able to provide bone marrow biopsy/aspirate material for biomarker analysis\n             or is willing to provide a newly obtained bone marrow biopsy/aspirate\n\n          -  For MM, Able to provide archival and newly obtained bone marrow aspirate/biopsy\n             material for biomarker analysis\n\n          -  For HL & NHL: Able to provide a lymph node biopsy for biomarker analysis (archival or\n             newly obtained at screening); for participants with programmed cell death ligand 1\n             (PD-L1) positive NHL an archival or newly obtained lymph node biopsy may be used for\n             study entry with additional biopsy at screening\n\n        Exclusion Criteria:\n\n          -  Is currently participating in or has participated in a study of an investigational\n             agent or using an investigational device within 4 weeks of the first dose of\n             treatment\n\n          -  Has a diagnosis of immunosuppression or is receiving systemic steroid therapy or any\n             other form of immunosuppressive therapy within 7 days prior to the first dose of\n             trial treatment\n\n          -  Has received a monoclonal antibody within 4 weeks prior to study Day 1 or has not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy\n             within 2 weeks prior to study Day 1 or who has not recovered from adverse events due\n             to a previously administered agent\n\n          -  Has undergone prior allogeneic hematopoetic stem cell transplantation within the last\n             5 years\n\n          -  Has a known additional malignancy that is progressing or requires active treatment\n\n          -  Has known clinically active central nervous system (CNS) involvement\n\n          -  Has an active autoimmune disease or a documented history of autoimmune disease, or a\n             syndrome that requires systemic steroids or immunosuppressive agents\n\n          -  Has evidence of interstitial lung disease\n\n          -  Has an active infection requiring intravenous systemic therapy\n\n          -  Has known psychiatric or substance abuse disorders that would interfere with\n             cooperation with the requirements of the trial\n\n          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of the trial\n\n          -  Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1),\n             anti-PD-L1, anti-programmed cell death ligand 2 (anti-PD-L2), anti-CD137, or\n             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including\n             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation\n             or checkpoint pathways)\n\n          -  Has a known Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C\n             (HCV) infection\n\n          -  Has known symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia\n\n          -  Has received a live vaccine within 30 days of planned start of study therapy\n\n          -  For MDS only: Is currently receiving treatment with any colony stimulating factors\n             and other hematopoetic cytokines within 2 weeks of enrollment into trial\n\n          -  For MM only: Has myeloma and a history of repeated infections, primary amyloidosis,\n             hyperviscosity, plasma cell leukemia, POEMS syndrome (polyneuropathy, organomegaly,\n             endocrinopathy, monoclonal gammopathy, and skin changes), Waldenstr\u00f6m's\n             macroglobulinemia, or Immunoglobulin M (IgM) myeloma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953692", 
            "org_study_id": "3475-013", 
            "secondary_id": "2013-001603-37"
        }, 
        "intervention": {
            "arm_group_label": [
                "MDS", 
                "Relapsed/Refractory MM", 
                "HL", 
                "MLBCL/PD-L1 positive NHL"
            ], 
            "intervention_name": "Pembrolizumab", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Call for Information (Investigational Site 0001)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Call for Information (Investigational Site 0008)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dominique Blazy", 
                    "phone": "33 147548990"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "MSD France"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Italy"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants Experiencing Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after end of treatment (up to 25 months)"
            }, 
            {
                "measure": "Number of Participants Discontinuing Treatment due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to end of treatment (up to 2 years)"
            }, 
            {
                "measure": "MDS: Overall Response Rate (ORR) Based on International Working Group (IWG) Criteria for MDS", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Relapsed/Refractory MM: ORR based on International Myeloma Working Group (IMWG) criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "HL: Complete Remission Rate (CRR) Based on IWG Criteria for Lymphoma", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "MLBCL/PD-L1 positive NHL: ORR Based on IWG Criteria for Lymphoma", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953692"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}